New tool launched to assist people living with hepatitis B in making decisions on health insurance <<read more here>> 

Liver Cancer Drug Watch

   
   

Compounds in Development for Liver Cancer

Updated Oct. 30, 2020

Drug Name 

Mechanism 

Company

Company Website

USA Status

Clinical Trial Website

Nexavar (Sorafenib) 

Raf/Mek/Erk inhibitor

Bayer

nexavar-us.com

Approved

N.A.

Stivarga (Regorafenib) 

Raf/kit/ret kinase inhibitor

Bayer

stivarga.com

Approved

N.A.

Opdivo (Nivolumab) 

PD1 inhibitor

Bristol Myers-Squibb

opdivo.com

Approved

N.A.

Opdivo (Nivolumab) + Yervoy (Ipilimumab) 

PD1 inhibitor/CTLA-4-blocking antibody

Bristol Myers-Squibb

bms.com

Approved

N.A.

Lenvima (Lenvatinib) 

VEGFR, PDGFR, FGFR, RET and c-Kit inhibitor

Eisai

lenvima.com

Approved

N.A.

Cabometyx (Cabozantinib) 

VEGFR2, c-MET, RET, KIT, FLT4, AXL inhibitor

Exelixis

cabometyx.com

Approved

N.A.

Tecentriq (Atezolizumab) + Avastin (Bevacizumab) 

PD-L1 monoclonal antibody/VEGFA inhibitor

Genentech

tecentriq.com

Approved

N.A.

Cyramza (Ramucirumab) 

VEGFR2 inhibitor

Eli Lilly and Co.

cyramza.com

Approved

N.A.

Imfinzi (Durvalumab) + Tremelimumab

PD-L1/CTLA-4 monoclonal antibody

AstraZeneca

astrazeneca.com

Phase II/III (phase II in combination with other drugs or procedures)

Clinical Trial

Cabozantinib + Opdivo (Nivolumab) ± Yervoy (Ipilimumab) 

MET inhibitor, PD1 inhibitor, CTLA-4-blocking antibody

Exelixis and Bristol-Myers Squibb

exelixis.com

Phase I/II

Clinical Trial

Cabozantinib + Tecentriq (Atezolizumab) vs. Nexavar (Sorafenib) 

MET inhibitor + PD-L1 monoclonal antibody vs. Raf/Mek/Erk inhibitor

Exelixis

exelixis.com

Phase III

Clinical Trial

Toripalamib + Lenvatinib

PD-1/VEGFR2, VEGFR3 antibody

 

 

Phase III

Clinical Trial

Nexavar (Sorafenib), as adjuvant 

Raf/Mek/Erk inhibitor

Bayer

nexavar.com

Phase II/III

Clinical Trial

Yiviva (YIV-906) + Sorafenib

Botanical

Yiviva Inc.

yiviva.com

Phase IIb

Clinical Trial

Milciclib

CDK2 Inhibitor

Tiziana Life Sciences

tizianalifesciences.com

Phase II

Clinical Trial

Galunisertib + Sorafenib

TGF-βR1/VEGFRs, C-KIT, PDGFRB, RAF inhibitor

Eli Lilly and Co.

lillytrials.com

Phase II

Clinical Trial

Tepotinib (MSC2156119J)

c-MET/HGF inhibitor

Merck KGaA, Darmstadt, Germany

emdgroup.com

Phase 1b/II

Clinical Trial

Galunisertib + Opdivo (Nivolumab)

TGF-βR1/PD-1 small molecular inhibitor

Eli Lilly and Co.

trials.lillytrialguide.com

Phase Ib/II

Clinical Trial

Spartalizumab +/- Capmatinib

PD-1/MET antibody

Novartis

novartis.com

Phase Ib/II

Clinical Trial

Pembrolizumab + Nexavar (Sorafenib)

PD-1/VEGFRs, C-KIT, PDGFRB, RAF inhibitor

Roswell Park Cancer Institute and Merck Sharpe & Dohme Corp.

roswellpark.org

Phase Ib/II

Clinical Trial

Pembrolizumab + Lenvima (Lenvatinib)

PD-1/VEGFR2, VEGFR3 antibody

Eisai

lenvima.com

Phase I/III

Clinical Trial

FGF401 +/- Spartalizumab

FGFR4 inhibitor/PD-1 antibody

Novartis, through a licensing agreement with EverNov, a subsidiary of Everest Medicines

everestmedicines.com

Phase I/II complete

Clinical Trial

Mogamulizumab + Opdivo (Nivolumab)

CCR4/PD-1 antibody

Kyowa Kirin Pharmaceutical Development, Inc. and Bristol-Myers Squibb

kyowakirin.com

Phase I/II

Clinical Trial

Pembrolizumab + Keytruda (Epacadostat)

PD-1/IDO1 antibody

Incyte Corporation

incyte.com

Phase I/II

Clinical Trial

Cabozantinib + Opdivo (Nivolumab)

MET inhibitor, VEGFRs/PD-1 antibody

Exelixis and Bristol-Myers Squibb

exelixis.com

Phase I/II

Clinical Trial (after resection)

Clinical Trial (with TACE)

XL888 + Pembrolizumab

Hsp90 inhibitor/PD-1 antibody

Merck Sharpe & Dohme Corp. and Exelixis

exelisis.com

Phase Ib

Clinical Trial 

Stivarga (Regorafenib) + Pembrolizumab

VEGFRs, FGFRs, C-KIT, PDGFRs, RAF/PD-1 antibody

Bayer and Merck Sharpe & Dohme Corp.

stivarga.com

Phase I

Clinical Trial

Avelumab + Axinitib

PD-L1/VEGFRs antibody, C-KIT, PDGFRs inhibitor

Pfizer

pfizer.com

Phase I

Clinical Trial 

Cyramza (Ramucirumab) + Imfinzi (Durvalumab)

VEGFR2/PD-L1 antibody

Eli Lilly and Co. and AstraZeneca

cyramza.com

Phase I

Clinical Trial